首页|他克莫司与霉酚酸联用的药物不良反应分析

他克莫司与霉酚酸联用的药物不良反应分析

扫码查看
目的 通过美国食品药品监督管理局(FDA)不良事件报告系统(FAERS)挖掘分析他克莫司(Tac)与霉酚酸(MPA)联合使用的药物不良反应(ADR)信号,为联合用药提供参考.方法 用OpenVigil 2.1平台检索2004年第一季度至2023年第一季度FAERS数据库中有关Tac与MPA联合使用的不良事件报告,用比例失衡分析法进行ADR信号挖掘.分析不良事件上报的人群特征,比较两药联合应用与其说明书中报告的ADR差别,筛选新的ADR.结果 共获取Tac与MPA联合使用的ADR报告32 866例,涉及男性患者17 455例(53.11%),女性患者11 445例(34.82%);40~<65岁患者占多数(13 174例,40.08%).发生频次较高的ADR主要有发热、感染和肾损害;信号强度较强的ADR主要有感染和皮肤毒性等;新发的ADR主要有血甲状旁腺素升高、心瓣膜关闭不全和急性精神病等.结论 联合使用Tac与MPA时,应对发生频次较高、信号强度较强及新发的ADR予以重视和监护.
Analysis of adverse drug reactions induced by tacrolimus combined with mycophenolic acid
Objective To mine and analyze the adverse drug reaction(ADR)signals caused by tacrolimus(Tac)combined with mycophenolic acid(MPA)based on Food and Drug Administration(FDA)adverse event reporting system(FAERS)database,so as to provide reference for clinical drug combination.Methods Open Vigil 2.1 platform was used to collect adverse events reports related to Tac and MPA between the first quarter of 2004 and the first quarter of 2023.Disproportionality analysis methods were used to mine the ADR risk signals.Characteristics of the population reporting adverse events were analyzed.ADR that arose from the combination of the two drugs were compared with those specified in the instructions of the two drugs in order to screen out new ADR.Results A total of 32 866 ADR reports of Tac and MPA used in combination were retrieved,in which 17 455 cases(53.11%)were males,11 445 cases(34.82%)were females.Cases were major in age from 40 to 65 years old(13 174 cases,40.08%).ADR with high frequency mainly included pyrexia,infections and renal impairment;ADR with strong signal strength mainly included infections and skin toxicity;new ADR mainly included blood parathyroid hormone increased,heart valve incompetence and acute psychosis.Conclusion When using Tac and MPA in combination,attention and care should be paid to the high frequency,strong signal strength and new signal of ADR.

tacrolimusmycophenolic acidadverse drug reactionsignal mining

陈鸿圣、刘爽、赵荣生

展开 >

北京大学第三医院药学部,北京 100191

北京大学医学部药物评价中心,北京 100191

北京大学药学院药事管理与临床药学系,北京 100191

他克莫司 霉酚酸 药物不良反应 信号挖掘

2024

中国临床药理学杂志
中国药学会

中国临床药理学杂志

CSTPCD北大核心
影响因子:1.91
ISSN:1001-6821
年,卷(期):2024.40(19)